Transmyocardial laser revascularization in ischemic cardiomyopathy

Grauhan, O.; Krabatsch, T.; Lieback, E.; Hetzer, Roland

doi:10.1016/s1053-2498(01)00238-8

Cited by 3 publications

(1 citation statement)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…14 It might also be the combination of growth factors enhancing the results of the treatment; however, experimental results are confl icting, and long-term clinical results of laser revascularization are unsatisfactory. 15 In DCM, the mechanism of action is unclear.…”

Section: Discussionmentioning

confidence: 99%

Intramyocardial Angiogenic Cell Precursor Injection for Cardiomyopathy

Arom

Ruengsakulrach

Jotisakulratana

2008

Asian Cardiovasc Thorac Ann

View full text Add to dashboard Cite

Stem cell therapy for heart failure is a rapidly progressing field. The objective of this study was to assess the safety, and short-term results of thoracoscopic direct injection of angiogenic cell precursors into patients with endstage cardiomyopathy. Cells were obtained from the patient's own blood, avoiding immunological concerns. The number of cells prior to injection was 29.1 +/- 18.9 x10(6). Forty-one patients with cardiomyopathy (mean age, 58.5 +/- 14.3 years) underwent stem cell injection; 21 had dilated cardiomyopathy and 20 had ischemic cardiomyopathy. Overall ejection fraction improved significantly by 4.8% +/- 7.5% at 149 +/- 98 days postoperatively. It increased from 25.9% +/- 8.6% to 28.7% +/- 9.8% in dilated cardiomyopathy, and from 26.6% +/- 5.8% to 33.6% +/- 7.8% in ischemic cardiomyopathy. New York Heart Association functional class was significantly better at 2 months in both groups. It was concluded that thoracoscopic intramyocardial angiogenic cell precursor injection is feasible and safe in patients with cardiomyopathy. The early results are good, and phase II trials are in progress.

show abstract

Section: Discussionmentioning

confidence: 99%